Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
← catalyst calendarNCT05769777 · readout in 1,757 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
999actual
Sites
174
Countries
Argentina, Australia, Brazil +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-03 | actual | When the study began enrolling |
| Primary completion | 2031-06-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-06-11 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Intervention
- Drug: Amlitelimab
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants who experienced Treatment-Emergent Adverse Events (TEAEs)
measured Baseline up to end of study (EOS) (Week 284)
Percentage of participants who experienced Treatment-Emergent Serious Adverse Events (TESAEs)
measured Baseline up to EOS (Week 284)
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed